Close Menu
Stratnews GlobalStratnews Global
    Facebook X (Twitter) Instagram
    Trending
    • India-Japan Space Cooperation: Key Advances and Future Prospects
    • Marvell Shares Tumble as Data Centre Forecast Disappoints AI Investors
    • Mars’ Mantle Found to Contain Ancient Fragments from Planet’s Chaotic Birth
    • FAA to Consolidate Offices, Move Staff to USDOT Headquarters
    • India Inaugurates Semiconductor OSAT Pilot Line Facility in Gujarat
    • Army Hospital Achieves Milestone with Robotic Cataract Surgery Using ALLY System
    • GST 2.0: India’s Second Tryst with Tax Reform
    • Nvidia Sees Trillion-Dollar AI Future Despite Investor Concerns
    Stratnews GlobalStratnews Global
    Write for Us
    Saturday, August 30
    • Space
    • Science
    • AI and Robotics
    • Industry News
    Stratnews GlobalStratnews Global
    Home » Novo Nordisk’s CagriSema Helps Diabetic Patients Lose 15.7% Weight in Trial

    Novo Nordisk’s CagriSema Helps Diabetic Patients Lose 15.7% Weight in Trial

    Arushi PandeyBy Arushi PandeyMarch 10, 2025 Science No Comments2 Mins Read
    Novo Nordisk’s CagriSema

    Novo Nordisk’s CagriSema Shows 15.7% Weight Loss in Type 2 Diabetes Trial

    Novo Nordisk announced on Monday that its experimental obesity drug, CagriSema, helped overweight or obese patients with type 2 diabetes lose an average of 15.7% of their body weight over 68 weeks. This latest phase III trial data is crucial for understanding the potential of Novo Nordisk’s CagriSema, especially after an earlier trial in people without diabetes showed lower-than-expected weight loss results.

    Promising Results from REDEFINE 2 Trial

    The new data comes from the REDEFINE 2 trial, which involved around 1,200 participants with type 2 diabetes and a body mass index (BMI) of 27 or higher. The trial used a flexible protocol, allowing patients to adjust their dosage throughout the study. By the end of the 68-week period, 61.9% of participants receiving CagriSema were on the highest dose.

    Patients treated with CagriSema achieved a 15.7% reduction in weight, compared to just 3.1% in the placebo group. Novo Nordisk highlighted that if all participants adhered fully to the treatment, the overall weight loss effect would remain at this level.

    How Novo Nordisk’s CagriSema Works

    CagriSema is a weekly injectable drug that combines two key components:

    • Semaglutide – the active ingredient in Wegovy, which mimics the gut hormone GLP-1 to regulate appetite and blood sugar levels.
    • Cagrilintide – a molecule that mimics the pancreatic hormone amylin, which helps control hunger.

    By combining these two hormones, CagriSema effectively reduces hunger while also managing blood glucose, making it a potential breakthrough treatment for patients struggling with both obesity and diabetes.

    A Key Step in Obesity and Diabetes Treatment

    The results from the REDEFINE 2 trial strengthen CagriSema’s case as a next-generation obesity drug, particularly for those with type 2 diabetes. Novo Nordisk’s findings will be closely watched as the company seeks regulatory approval and potential commercialisation of the drug.

    With inputs from Reuters

    Author

    • Arushi Pandey
      Arushi Pandey

      View all posts
    Featured
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp
    Arushi Pandey

      Keep Reading

      Marvell Shares Tumble as Data Centre Forecast Disappoints AI Investors

      Mars’ Mantle Found to Contain Ancient Fragments from Planet’s Chaotic Birth

      FAA to Consolidate Offices, Move Staff to USDOT Headquarters

      India Inaugurates Semiconductor OSAT Pilot Line Facility in Gujarat

      Army Hospital Achieves Milestone with Robotic Cataract Surgery Using ALLY System

      Nvidia Sees Trillion-Dollar AI Future Despite Investor Concerns

      Add A Comment
      Leave A Reply Cancel Reply

      Latest Posts

      India-Japan Space Cooperation: Key Advances and Future Prospects

      August 30, 2025

      Marvell Shares Tumble as Data Centre Forecast Disappoints AI Investors

      August 29, 2025

      Mars’ Mantle Found to Contain Ancient Fragments from Planet’s Chaotic Birth

      August 29, 2025

      FAA to Consolidate Offices, Move Staff to USDOT Headquarters

      August 29, 2025

      India Inaugurates Semiconductor OSAT Pilot Line Facility in Gujarat

      August 29, 2025

      Army Hospital Achieves Milestone with Robotic Cataract Surgery Using ALLY System

      August 29, 2025

      GST 2.0: India’s Second Tryst with Tax Reform

      August 28, 2025

      Nvidia Sees Trillion-Dollar AI Future Despite Investor Concerns

      August 28, 2025

      IN-SPACe Facilitates Transfer of ISRO Technologies to Boost Indian Manufacturing

      August 28, 2025

      Egusi Seeds from Nigeria Soar to Space as a Symbol of African Heritage

      August 28, 2025

      Subscribe to News

      Get the latest sports news from NewsSite about world, sports and politics.

      • Astronomical Events
      • Space Missions
      • Industry News
      • Science
      StratNewsGlobal Tech
      Facebook X (Twitter) Instagram LinkedIn YouTube
      © 2025 StratNews Global, A unit of BharatShakti Communications LLP
      • About Us
      • Contributors
      • Copyright
      • Contact
      • Write for Us

      Type above and press Enter to search. Press Esc to cancel.